Pfizer (PFE) has FDA approval for a new drug that "blocks the CCR5 co-receptor that serves as a main doorway for the HIV virus into immune cells." It will be marketed as Selzentry and is the first of a new generation of drugs that will bring new pharma R&D to the fight against AIDs.
According to industry analysts, the drug could have annual sales of $500 million within three to four years.
A January research study described the new treatment "a potent new class of antiyirals for the treatment of HIV infection"
Given the PR beating the drug companies take, it is good to see some positive news.
Pfizer could use it. The company is trying to rebuild in the face of generic competition. In an interview with The Associated Press a company executive was upbeat about progress: "I think so far we’re on track to deliver on the goal of tripling the number of compounds in the Phase III pipeline by 2009," said John LaMattina, president of Pfizer’s global research and development.
The company’s shares closed at $24.11 today, within hailing distance of their 52-week low.
Douglas A. McIntyre
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
